Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession

August 11, 2016 11:46 AM EDT
Get Alerts BLRX Hot Sheet
Price: $1.02 --0%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 50 | New: 20
Trade BLRX Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Roth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results and appointment of a new CEO, as announced early Thursday.

Analyst Joseph Pantginis commented, The company has several important catalysts slated by year-end, which should be able to address the recent Nasdaq de-listing notice (January 2017 deadline). From a data standpoint, BL-8040 remains the lead value driver with 1) full data from the Phase IIa in r/rAML in September 2016 at SOHO and 2) partial data from the ongoing Phase II in stem cell mobilization by year-end (full data by end of 2017).

The BL-8040 program in pancreatic cancer program will also get running this quarter, first with the Phase IIa combo with Merck's (NYSE: MRK) Keytruda and then an IST with MDAnderson in a Phase IIa by year-end. Beyond response rates, key assessments will include changes in the tumor microenvironment, especially impact on infiltrating Tcells. Omega is continuing to launch BL-5010 in different geographies and BLRX projects $2-4 million royalty potential at peak. A second OTC indication is also in development with ~the same royalty potential. The company will be starting the regulatory process for BL-7010 as a GRAS food additive for gluten sensitivity.

For an analyst ratings summary and ratings history on BioLineRx click here. For more ratings news on BioLineRx click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Roth Capital

Add Your Comment